Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
* Safety and tolerability of three regimens of intravesically administered BC-819/PEI and BCG (number of participants with AEs, discontinuations due to AEs)
* Recurrence after treatment with BC-819/PEI and BCG
* Approximately 38 patients with superficial transitional cell carcinoma TCC) of the bladder
* After initial evaluation and qualification, patients will be randomized to one of three treatment groups, either alternating, sequential or twice weekly
Transitional Cell Carcinoma of Bladder
DRUG: BC-819/PEI|DRUG: BCG Vaccine
Safety and tolerability of three regimens of intravesically administered BC-819/PEI and BCG by number of subjects with AEs and change from baseline for clinical safety laboratory tests, 3 months
Recurrence of bladder cancer after treatment with BC-819/PEI and BCG, 3 months
* Safety and tolerability of three regimens of intravesically administered BC-819/PEI and BCG (number of participants with AEs, discontinuations due to AEs)
* Recurrence after treatment with BC-819/PEI and BCG
* Approximately 38 patients with superficial transitional cell carcinoma TCC) of the bladder
* After initial evaluation and qualification, patients will be randomized to one of three treatment groups, either alternating, sequential or twice weekly